AVTX

Company Overview — What Does Avalo Therapeutics, Inc. Do?

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Avalo Therapeutics, Inc. (AVTX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Garry A. Neil and employs approximately 40 people, headquartered in Baltimore, Maryland. With a market capitalization of $381M, AVTX is one of the notable companies in the Healthcare sector.

Avalo Therapeutics, Inc. (AVTX) Stock Rating — Reduce (April 2026)

As of April 2026, Avalo Therapeutics, Inc. receives a Reduce rating with a composite score of 29.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AVTX ranks #2,438 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Avalo Therapeutics, Inc. ranks #303 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AVTX Stock Price and 52-Week Range

Avalo Therapeutics, Inc. (AVTX) currently trades at $13.66. The stock lost $0.55 (3.9%) in the most recent trading session. The 52-week high for AVTX is $20.72, which means the stock is currently trading -34.1% from its annual peak. The 52-week low is $3.39, putting the stock 302.9% above its annual trough. Recent trading volume was 726K shares, suggesting relatively thin trading activity.

Is AVTX Overvalued or Undervalued? — Valuation Analysis

Avalo Therapeutics, Inc. (AVTX) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.37x, versus the sector average of 2.75x. The price-to-sales ratio is 1457.00x, compared to 1.66x for the average Healthcare stock.

At current multiples, Avalo Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Avalo Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Avalo Therapeutics, Inc. (AVTX) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -50.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -35.6% versus the sector average of -33.1%.

On a margin basis, Avalo Therapeutics, Inc. reports gross margins of 386.8%, compared to 71.5% for the sector. The operating margin is -5165.1% (sector: -66.1%). Net profit margin stands at 9251.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AVTX Debt, Balance Sheet, and Financial Health

Avalo Therapeutics, Inc. has a debt-to-equity ratio of 40.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $27M.

AVTX has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Avalo Therapeutics, Inc. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Avalo Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Avalo Therapeutics, Inc. reported revenue of $249,000 and earnings per share (EPS) of $-5.84. Net income for the quarter was $-42M. Gross margin was 386.8%. Operating income came in at $-66M.

In FY 2025, Avalo Therapeutics, Inc. reported revenue of $59,000 and earnings per share (EPS) of $-5.84. Net income for the quarter was $-78M. Revenue grew -86.6% year-over-year compared to FY 2024. Operating income came in at $-73M.

In Q3 2025, Avalo Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.19. Net income for the quarter was $-31M. Operating income came in at $-19M.

In Q2 2025, Avalo Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.92. Net income for the quarter was $-21M. Operating income came in at $-19M.

Over the past 8 quarters, Avalo Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $249,000. Investors analyzing AVTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AVTX Dividend Yield and Income Analysis

Avalo Therapeutics, Inc. (AVTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AVTX Momentum and Technical Analysis Profile

Avalo Therapeutics, Inc. (AVTX) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AVTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Avalo Therapeutics, Inc. (AVTX) ranks #303 out of 838 stocks based on the Blank Capital composite score. This places AVTX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AVTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AVTX vs S&P 500 (SPY) comparison to assess how Avalo Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

AVTX Next Earnings Date

No upcoming earnings date has been announced for Avalo Therapeutics, Inc. (AVTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AVTX? — Investment Thesis Summary

The quantitative profile for Avalo Therapeutics, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. Price momentum is positive at 65/100, suggesting the trend favors buyers. High volatility (stability score 34/100) increases portfolio risk.

In summary, Avalo Therapeutics, Inc. (AVTX) earns a Reduce rating with a composite score of 29.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AVTX stock.

Related Resources for AVTX Investors

Explore more research and tools: AVTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AVTX head-to-head with peers: AVTX vs AZN, AVTX vs SLGL, AVTX vs VMD.